Standardy péče o pacienty s revmatoidní artritidou dle doporučení EULAR
Je nutné sdílet léčebná rozhodnutí s pacientem?
Authors:
L. Šedová; J. Tomasová-Studýnková
Authors‘ workplace:
Revmatologický ústav Praha
Published in:
Čes. Revmatol., 27, 2019, No. 4, p. 211-217.
Category:
Review Article
Overview
In 2014, the European League against Rheumatism published standards of care for patients with rheumatoid arthritis to be implemented in all European Union countries by 2020. They aim to ensure comparable evidence-based musculoskeletal health care. One of the main prerequisites for this standard care is the shared decision between the patient and the physician on all aspects of the disease, which requires detailed information to the patient. This article discusses not only 16 points of standards, but also the importance of shared decision making, which should help the patient understand the nature of the disease, improve collaboration with the physician and make an informed decision.
Keywords:
shared decision – standards of care – treat to target – guidelines for the management of rheumatoid arthritis
Sources
1. Wolfe F, Michaud K. Resistance of rheumatoid arthritis patients to changing therapy: discordance between disease activity and patients’ treatment choices. Arthritis Rheum 2007; 56: 2135–2142.
2. Kvien TK, Heiberg T. Patient perspective in outcome assessments-perceptions or something more? J Rheumatol 2003; 30: 873–876.
3. Kirwan JR, Fries JF, Hewlett S, Osborne SH. Patient Perspective: Choosing or Developing Instruments. J Rheumatol 2011; 38(8): 1716–1719. doi: https://doi.org/10.3899/jrheum.110390
4. Hewlett SA. Patients and clinicians have different perspectives on outcomes in arthritis. J Rheumatol 2003; 30: 877–879.
5. Viller F, Guillemin F, Briançon S, Moum T, Suurmeijer T, van den Heuvel W. Compliance to drug treatment of patients with rheumatoid arthritis: a 3-year longitudinal study. J Rheumatol 1999; 26: 2114–2122.
6. Smolen J, Landewé R, Breedveld F, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease–modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964–975.
7. Smolen J, Landewé R, Breedveld F, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2014; 73: 492–509.
8. Smolen JS, Aletaha D, Bijlsma JWJ, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69: 631–637.
9. Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force Ann Rheum Dis 2016; 75: 3–15.
10. Kobue B, Moch S, Watermeyer J. It’s so hard taking pills when you don’t know what they’re for: a qualitative study of patients’ medicine taking behaviors and conceptualization of medicines in the context of rheumatoid arthritis. BMC Health Serv Res 2017; 26(17): 303.
11. Wabe N, Wiese MD. Treating rheumatoid arthritis to target: physician and patient adherence issues in contemporary rheumatoid arthritis therapy. J Eval Clin Pract 2017; 23: 486–493.
12. Fraenkel L, Peters E, Charpentier P, et al. Decision tool to improve the quality of care in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 977–985.
13. Barton JL, Imboden J, Graf J, Glidden D, Yelin EH, Schillinger D. Patient-physician discordance in assessments of global disease severity in rheumatoid arthritis. Arthritis Care Res 2010; 62: 857–864.
14. Smolen JS, Strand V, Koenig AS, Szumski A, Kotak S, Jones TV. Discordance between patient and physician assessments of global disease activity in rheumatoid arthritis and association with work productivity. Arthritis Research & Therapy 2016; 18: 114.
15. Verhoef LM, Selten EMH, Vriezekolk JE, et al. The patient perspective on biologic DMARD dose reduction in rheumatoid arthritis: a mixed methods study. Rheumatology 2018; 57: 1947–1955.
16. de Wit MP, Smolen JS, Gossec L, van der Heijde DM. Treating rheumatoid arthritis to target: the patient version of the international recommendations. Ann Rheum Dis 2011; 70: 891–895.
17. Stoffer MA, Smolen JS, Woolf A, et. al. Development of patient-centred standards of care for rheumatoid arthritis in Europe: the eumusc.net project. Ann Rheum Dis 2014; 73: 902–905.
18. De Mits S, Lenaerts J, Vander Cruyssen B. A Nationwide survey on patient’s versus physician’s evaluation of biological therapy in rheumatoid arthritis in relation to disease activity and route of administration: The Be-Raise Study. PLoS One 2016; 11(11): e0166607. doi: 10.1371/journal.pone.0166607. eCollection 2016.
Labels
Dermatology & STDs Paediatric rheumatology RheumatologyArticle was published in
Czech Rheumatology
![Issue 4](https://www.prolekare.cz/media/cache/resolve/journal_issue/media/image_pdf/d7fc0727e6236404195cb431bada9580.jpeg)
2019 Issue 4
Most read in this issue
- Paraneoplastic syndrom
- Recommendations of the Czech Society for Rheumatology for the treatment of gout
- Impact of inflammatory granulomas in rheumatic diseases
- The importance of achieving remission in patients with rheumatoid arthritis